Piermont Capital Management’s Momenta Pharmaceuticals, Inc. MNTA Stock Holding History

Piermont Capital Management’s Portfolio MNTA Stock Details MNTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-26,260	Closed	-$431K	–	268
2015 Q3	$431K	Hold	26,260	–	–	0.14%	161
2015 Q2	$599K	Buy	+26,260	New	+$523K	0.18%	130

Other funds holding MNTA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

DCM

Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Piermont Capital Management's MNTA Position: Q4 2015 in Review

Piermont Capital Management sold out of Momenta Pharmaceuticals, Inc. (MNTA) in Q4 2015, closing a stake of 26,260 shares — an estimated $431K sold.

Piermont Capital Management first reported a position in MNTA in Q2 2015 and held it in 2 quarters. The position peaked at $599K in Q2 2015. 164 funds tracked by Wall St. Rank hold MNTA as of Q4 2015.

Piermont Capital Management reported no remaining Momenta Pharmaceuticals, Inc. position as of Q4 2015 after selling out during the quarter.
Piermont Capital Management sold 26,260 Momenta Pharmaceuticals, Inc. shares in Q4 2015, an estimated $431K.
Piermont Capital Management first reported a position in Momenta Pharmaceuticals, Inc. in Q2 2015 and held it in 2 quarters.
Piermont Capital Management's Momenta Pharmaceuticals, Inc. position peaked at $599K in Q2 2015.
164 funds tracked by Wall St. Rank held Momenta Pharmaceuticals, Inc. as of Q4 2015.

Based on Piermont Capital Management's 13F filing for Q4 2015, filed 11 Feb 2016.